FATE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FATE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-05), Fate Therapeutics's current share price is $3.66. Fate Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.40. Fate Therapeutics's Cyclically Adjusted PS Ratio for today is 9.15.
The historical rank and industry rank for Fate Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Fate Therapeutics's highest Cyclically Adjusted PS Ratio was 243.79. The lowest was 4.02. And the median was 17.48.
FATE's Cyclically Adjusted PS Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Fate Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.019. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.40 for the trailing ten years ended in Mar. 2024.
The historical data trend for Fate Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 14.14 | 11.72 | 5.16 | 9.37 | 18.47 |
For the Biotechnology subindustry, Fate Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Fate Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 3.66 | / | 0.4 | |
= | 9.15 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Fate Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.019 | / | 131.7762 | * | 131.7762 | |
= | 0.019 |
Current CPI (Mar. 2024) = 131.7762.
Fate Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.014 | 100.684 | 0.018 |
201509 | 0.036 | 100.392 | 0.047 |
201512 | 0.037 | 99.792 | 0.049 |
201603 | 0.046 | 100.470 | 0.060 |
201606 | 0.036 | 101.688 | 0.047 |
201609 | 0.032 | 101.861 | 0.041 |
201612 | 0.028 | 101.863 | 0.036 |
201703 | 0.025 | 102.862 | 0.032 |
201706 | 0.025 | 103.349 | 0.032 |
201709 | 0.025 | 104.136 | 0.032 |
201712 | 0.023 | 104.011 | 0.029 |
201803 | 0.019 | 105.290 | 0.024 |
201806 | 0.019 | 106.317 | 0.024 |
201809 | 0.019 | 106.507 | 0.024 |
201812 | 0.026 | 105.998 | 0.032 |
201903 | 0.041 | 107.251 | 0.050 |
201906 | 0.043 | 108.070 | 0.052 |
201909 | 0.036 | 108.329 | 0.044 |
201912 | 0.037 | 108.420 | 0.045 |
202003 | 0.033 | 108.902 | 0.040 |
202006 | 0.069 | 108.767 | 0.084 |
202009 | 0.087 | 109.815 | 0.104 |
202012 | 0.182 | 109.897 | 0.218 |
202103 | 0.119 | 111.754 | 0.140 |
202106 | 0.142 | 114.631 | 0.163 |
202109 | 0.149 | 115.734 | 0.170 |
202112 | 0.178 | 117.630 | 0.199 |
202203 | 0.191 | 121.301 | 0.207 |
202206 | 0.192 | 125.017 | 0.202 |
202209 | 0.154 | 125.227 | 0.162 |
202212 | 0.456 | 125.222 | 0.480 |
202303 | 0.601 | 127.348 | 0.622 |
202306 | 0.009 | 128.729 | 0.009 |
202309 | 0.020 | 129.860 | 0.020 |
202312 | 0.017 | 129.419 | 0.017 |
202403 | 0.019 | 131.776 | 0.019 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Fate Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
J Scott Wolchko | director, officer: President and CEO | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Dulac Edward J Iii | officer: Chief Financial Officer | FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121 |
Bahram Valamehr | officer: Chief Development Officer | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121 |
Cindy Tahl | officer: See Remarks | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121 |
Redmile Group, Llc | director, 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Yuan Xu | director | C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Brian T. Powl | officer: Chief Commercial Officer | C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131 |
Yu-waye Chu | officer: See Remarks | FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121 |
John Mendlein | director | |
Mark Plavsic | officer: Chief Technical Officer | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121 |
Shefali Agarwal | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Karin Jooss | director | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Timothy P Coughlin | director | 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075 |
Robert Hershberg | director | 3005 FIRST AVENUE, SEATTLE WA 98121 |
Robert S Epstein | director |
From GuruFocus
By Marketwired • 10-25-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 05-03-2023
By Business Wire Business Wire • 06-09-2023
By Business Wire • 06-22-2023
By sperokesalga sperokesalga • 03-20-2023
By PRNewswire PRNewswire • 03-18-2023
By PRNewswire PRNewswire • 03-17-2023
By Marketwired • 08-28-2023
By Marketwired • 08-08-2023